{
  "abstract": "Trichomonas vaginalis affects 5.3% of women globally.1 It is associated with multiple adverse outcomes including pelvic inflammatory disease, infertility, HIV and sexually transmitted infection (STI) acquisition/transmission, cervical cancer and adverse birth outcomes.1 5-nitroimidazoles (metronidazole [MTZ], tinidazole [TDZ], secnidazole [SEC]) are the only drug class approved for treatment.2 MTZ became available in 1960, with reports of drug resistance emerging 2 years later.1 TDZ and SEC drug-resistant cases have also been published.1 Diagnosing and treating resistant T. vaginalis is challenging, particularly during pregnancy.",
  "authors": [
    {
      "affiliations": [
        "Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA"
      ],
      "name": "Marisa R Young"
    },
    {
      "affiliations": [
        "Department of Medicine, Division of Infectious Diseases, The University of Alabama at Birmingham Department of Medicine, Birmingham, Alabama, USA"
      ],
      "name": "Olivia T Van Gerwen"
    },
    {
      "affiliations": [
        "Department of Medicine, Division of Infectious Diseases, The University of Alabama at Birmingham Department of Medicine, Birmingham, Alabama, USA"
      ],
      "name": "Christina A Muzny"
    }
  ],
  "title": "The persistent parasite: diagnosis and treatment of resistant Trichomonas vaginalis infection",
  "uid": "368fa7e6-b35d-5928-b09f-5222f1e7cf96"
}